• 1. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 2. Always a matter of interpretation: inferring student knowledge and understanding from research data
  Chem. Educ. Res. Pract., 2017,18, 7-12
• 3. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. Achieving molecular stability of racemic 4-O-benzyl-myo-inositol-1,3,5-orthoformate through crystal formation?
  Richa Sardessai,Shobhana Krishnaswamy,Mysore S. Shashidhar CrystEngComm, 2012,14, 8010-8016

Introduction to 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine (CAS No. 1014614-11-9)

4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine (CAS No. 1014614-11-9) is a highly specialized heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the pyrrole-bipyridine class, a structural motif widely recognized for its potential in drug discovery due to its ability to form stable metal complexes and interact with biological targets. The presence of both bromo and cyclopropyl substituents on the pyrrole-bipyridine core introduces unique electronic and steric properties, making it a valuable scaffold for developing novel therapeutic agents.

The bromo substituent at the 4-position provides a versatile handle for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are essential for constructing more complex molecular architectures. Additionally, the cyclopropyl group at the 2-position contributes to the overall steric environment of the molecule, influencing its binding affinity and selectivity when interacting with biological targets. These structural features make 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine particularly interesting for medicinal chemists seeking to design molecules with enhanced pharmacological activity.

In recent years, there has been growing interest in exploring the therapeutic potential of pyrrole-bipyridine derivatives, particularly in the context of oncology and infectious diseases. The bipyridine moiety is well-known for its ability to chelate transition metals, forming complexes that exhibit potent antitumor and antimicrobial properties. For instance, platinum(II) complexes derived from bipyridine ligands have been extensively studied as anticancer agents due to their ability to induce DNA damage and inhibit tumor growth. Similarly, ruthenium(II) complexes based on bipyridine ligands have shown promising activity against drug-resistant bacterial strains.

The incorporation of the cyclopropyl group into the pyrrole-bipyridine scaffold has been shown to modulate the pharmacokinetic properties of these compounds. Cyclopropyl groups are known to enhance metabolic stability by resisting oxidative ring opening, thereby prolonging the half-life of drug candidates. This feature is particularly advantageous in drug development, where long-term efficacy and bioavailability are critical factors. Furthermore, the bromo substituent can be selectively removed or replaced with other functional groups through transition-metal-catalyzed reactions, providing a flexible platform for generating a diverse library of derivatives.

Recent studies have highlighted the potential of 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine as a key intermediate in the synthesis of metal-based therapeutics. For example, researchers have demonstrated that this compound can be used to prepare novel ruthenium(II) complexes with enhanced cytotoxicity against various cancer cell lines. These complexes exhibit superior selectivity over traditional platinum-based chemotherapeutics by preferentially targeting hypoxic tumor microenvironments. The ability of these complexes to generate reactive oxygen species (ROS) has also been exploited for their radiosensitizing effects, potentially synergizing with radiation therapy.

Another area of interest is the use of 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine in developing antiviral agents. The bipyridine scaffold has been shown to interact with viral enzymes and proteins, inhibiting replication and propagation. For instance, derivatives of this compound have demonstrated activity against HIV reverse transcriptase (RT), an essential enzyme for viral replication. The cyclopropyl group has been found to improve binding affinity by filling hydrophobic pockets within the enzyme active site, while the bromo substituent allows for further derivatization to optimize potency and selectivity.

The synthesis of 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine involves multi-step organic transformations that highlight its synthetic versatility. Starting from commercially available precursors such as 2-aminoethylamine and cyclopropanecarboxaldehyde, the pyrrole ring can be constructed via condensation reactions followed by cyclization under acidic conditions. The introduction of the bromo substituent is typically achieved using brominating agents like N-bromosuccinimide (NBS) in polar aprotic solvents such as dimethylformamide (DMF). Subsequent functionalization at the 2-position can be performed using Grignard reagents or organolithium compounds to introduce various alkyl or aryl groups.

The pharmacological evaluation of 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine has revealed intriguing properties that warrant further investigation. In vitro studies have shown that this compound exhibits moderate affinity for certain metal ions, suggesting its potential as a ligand for developing metal-based therapeutics. Additionally, preliminary toxicity assays indicate that it is well-tolerated at subtoxic concentrations, making it a promising candidate for further preclinical development.

The future directions for research on 4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine include exploring its interactions with biological targets at a structural level using techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy. These studies will provide insights into how modifications at different positions on the molecule affect binding affinity and selectivity. Furthermore, computational modeling techniques can be employed to predict optimal conformations and functional groups that enhance pharmacological activity.

In conclusion,4-Bromo-2-cyclopropyl-1H-pyrrolo[2,3-bpyridine (CAS No. 1014614-11-9) represents a structurally unique and synthetically versatile compound with significant potential in pharmaceutical research. Its ability to form stable metal complexes and interact with biological targets makes it an attractive scaffold for developing novel therapeutic agents across multiple disease areas. With ongoing advancements in synthetic chemistry and pharmacological evaluation, this compound is poised to contribute valuable insights into drug discovery efforts aimed at addressing unmet medical needs.

• 1014613-55-8(2-cyclobutyl-1H-Pyrrolo[2,3-b]pyridine)
• 934619-83-7(1H-Pyrrolo[2,3-b]pyridine, 3-broMo-2-propyl-)
• 1014613-50-3(2-Cyclopropyl-1H-pyrrolo2,3-bpyridine)
• 1014613-61-6(2,1,3-Benzothiadiazole-1(3H)-propanol, 3-(2-fluorophenyl)-α-[(methylamino)methyl]-, 2,2-dioxide, (αS)-)
• 27257-18-7(1H-Pyrrolo[2,3-b]pyridine,2-(1-methylethyl)-)
• 1187449-10-0(1H-Pyrrolo[2,3-b]pyridine, 4-bromo-5-chloro-2-cyclopropyl-)
• 1014613-94-5(2-(1-methylcyclopropyl)-1H-Pyrrolo[2,3-b]pyridine)
• 678987-71-8(2-cyclopropyl-1,8-Naphthyridine)
• 1014613-59-2(2-(6-(4-(4-benzylphthalazin-1-yl)piperazin-1-yl)pyridin-3-yl)propan-2-ol)
• 1187449-21-3(1H-Pyrrolo[2,3-b]pyridine, 4-bromo-2-cyclopropyl-5-fluoro-)